Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label study of fixed-dose solifenacin + tamsulosin in men with LUTS associated with BPH
2008-001212-20Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- May 2009
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of solifenacin and tamsulosin in benign prostatic hyperplasia (BPH) (2 arms), sponsored by Astellas Pharma. Primary endpoint: Incidence, severity and relationship of adverse events to study drug. Started May 2009; status: completed.
02
Drugs
solifenacintamsulosin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on 2008-001212-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001212-20.